Table 2.
Overall Survival by Treatment Arm: Risk-Stratified Analysis
| Treatment Arm by Risk Group | No. of Patients | Overall Survival
|
Analysis
|
P | ||
|---|---|---|---|---|---|---|
| Median (Months) | 95% CI | HR | 95% CI | |||
| Low | ||||||
| FOLFOX | 247 | 27.5 | 22.6 to 29.9 | 1 | ||
| IFL | 146 | 18.2 | 15.8 to 20.7 | 1.68 | 1.35 to 2.08 | < .0001 |
| IROX | 135 | 19.7 | 17.2 to 23.3 | 1.47 | 1.18 to 1.84 | .0006 |
| Intermediate | ||||||
| FOLFOX | 384 | 19.2 | 17.9 to 20.8 | 1 | ||
| IFL | 227 | 13.8 | 12.2 to 16.4 | 1.48 | 1.25 to 1.75 | < .0001 |
| IROX | 196 | 17.8 | 16.1 to 19.8 | 1.29 | 1.08 to 1.55 | .0047 |
| High | ||||||
| FOLFOX | 60 | 10.7 | 8.2 to 12.4 | 1 | ||
| IFL | 55 | 9.4 | 6.3 to 12.4 | 1.27 | 0.87 to 1.85 | .2086 |
| IROX | 49 | 9.1 | 6.0 to 12.3 | 1.27 | 0.87 to 1.87 | .2186 |
Abbreviations: HR, hazard ratio; FOLFOX, oxaliplatin, fluorouracil, and leucovorin; IFL, irinotecan plus bolus fluorouracil and leucovorin; IROX, irinotecan and oxaliplatin.